Baijin Life Science Holdings Limited

Baijin Life Science Holdings Limited

MNNGF
Baijin Life Science Holdings LimitedUS flagOther OTC
0.08
USD
- -
- -
58.00MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
1.92
1.93
1.48
1.26
1.06
0.96
0.59
0.17
0.18
0.14
0.08
0.2
Basic EPS, GAAP
0.21
0.07
-0.08
-0.14
-0.73
-0.24
-1.48
-0.21
-0.04
0.01
-0.01
- -
Free Cash Flow per Basic Share
0.14
-0.12
-0.15
-0.61
0.46
-0.13
-0.01
-0.07
- -
-0.04
-0.01
-0.05
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.47
-0.5
-0.14
-0.26
-0.97
-1.23
-2.63
0.02
-1.59
-0.91
-0.85
-0.78
Tangible Book Value per Share
2.85
1.91
2.21
1.73
1.33
1.11
0.45
0.18
0.1
0.13
0.09
0.18
Basic Weighted Avg Shares
140
140
142
168
177
178
191
249
355
603
645
694
Sales/Revenue/Turnover
268
271
210
212
187
171
112
43
63
87
54
136
Operating Margin (%)
11.34
5.81
-9.1
-10.97
-12.64
-19.92
-37.29
-99.4
-16.52
12.66
-18.74
4.59
Depreciation Expense
6
6
4
2
2
2
4
2
1
1
2
7
Net Income, GAAP
30
10
-11
-24
-130
-43
-282
-52
-15
9
-7
- -
Effective Tax Rate (%)
7.58
37.34
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
11.02
3.71
-5.21
-11.25
-69.27
-25
-251.68
-119.53
-24.68
9.99
-13.88
-0.23
Working Capital
310
170
304
272
141
53
75
44
34
78
80
177
LT Debt
- -
- -
- -
- -
- -
- -
6
- -
1
- -
41
82
Total Equity
399
268
314
290
237
198
85
46
36
78
113
156
Return on Invested Capital (%)
- -
2.65
- -
- -
- -
- -
- -
- -
- -
18.58
- -
- -
Return on Capital (%)
- -
5.79
- -
- -
- -
- -
- -
- -
- -
-1.8
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.05%
26.52%
38.2%
Free Cash Flow
-74.27%
-149.5%
396.87%
Net Income, GAAP
25.46%
-117.9%
-95.76%
Sales/Revenue/Turnover
6%
27.26%
152.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
54
2025
- -
- -
- -
- -
136
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Sze Ming Cheung
Full Time Employees
84
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Wings Building Central Hong Kong
IPO Date
Apr 10, 2015
Business
Baijin Life Science Holdings Limited, formerly Affluent Partners Holdings Limited, is an investment holding company principally engaged in the manufacture, design, production, and wholesale distribution of pearls and jewelry products; strategic investments and financial services including real estate financial assets and investments in associates; skincare solutions under the FO brand name with franchise licensing; skincare testing products; and scientific and pharmaceutical research services. The company operates through segments such as sale of pearls and jewelry products, which generates the majority of revenue primarily from the USA, with additional presence in Germany, Italy, the UK, PRC, Japan, and other countries. Founded in 2014 and headquartered in Hong Kong, it changed its name to Baijin Life Science Holdings Limited in January 2025 to reflect a strategic shift toward life sciences, alongside ongoing operations in jewelry wholesale and skincare.